



RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Eucrisa is indicated for topical treatment of mild to moderate atopic dermatitis. Atopic dermatitis, a chronic inflammatory skin disease, is often referred to as "eczema," which is a general term for the several types of inflammation of the skin. Atopic dermatitis is the most common of the many types of eczema and onset typically begins in childhood and can last through adulthood. The cause of atopic dermatitis is a combination of genetic, immune and environmental factors. Eucrisa (crisaborole) is a phosphodiesterase 4 (PDE-4) inhibitor. PDE-4 inhibition results in increased intracellular cyclic adenosine monophosphate (cAMP) levels. The specific mechanism(s) by which crisaborole exerts its therapeutic action for the treatment of atopic dermatitis is not well defined (1).

Regulatory Status

FDA-approved indication: Eucrisa is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older (1).

Topical corticosteroids are used in the management of atopic dermatitis in both adults and children and are the mainstay of anti-inflammatory therapy. Topical calcineurin inhibitors (TCI) are a second class of anti-inflammatory therapy. They are naturally produced by *Streptomyces* bacteria and inhibit calcineurin dependent T-cell activation, blocking the production of pro-inflammatory cytokines and mediators of the AD inflammatory reaction. They have also been demonstrated to affect mast cell activation, and tacrolimus decreases both the number and costimulatory ability of epidermal dendritic cells. Topical calcineurin inhibitors are only approved for use in patients 2 years of age and older (2).

The safety and effectiveness of Eucrisa have been established in pediatric patients aged 3 months and older for topical treatment of mild to moderate atopic dermatitis (1).

Summary

Eucrisa (crisaborole) is indicated for topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Eucrisa is a phosphodiesterase 4 (PDE-4) inhibitor. The most common adverse reaction occurring in $\geq 1\%$ in subjects is application site pain. Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with Eucrisa. The safety



**BlueCross
BlueShield**

Federal Employee Program.

EUCRISA (crisaborole)

and effectiveness of Eucrisa have been established in pediatric patients aged 3 months and older for topical treatment of mild to moderate atopic dermatitis (1).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of Eucrisa while maintaining optimal therapeutic outcomes

References

1. Eucrisa [package insert]. New York, NY: Pfizer Inc.; April 2023.
2. Eichenfield L, Tom W, etc. Guidelines of care for the management of atopic dermatitis. Journal of American Academy of Dermatology. July 2014. Volume 71:1 pg. 116-132



APPENDIX I

Relative Potency of Topical Calcineurin Inhibitors			
	Drug	Dosage Form	Strength
I.	<i>Medium potency</i>		
	Tacrolimus	Ointment	0.1%
II.	<i>Low potency</i>		
	Tacrolimus	Ointment	0.03%
	Pimecrolimus	Cream	1%

APPENDIX II

Relative Potency of Selected Topical Corticosteroid Products			
	Drug	Dosage Form	Strength
I.	<i>Very high potency</i>		
	Augmented betamethasone dipropionate	Ointment, Gel	0.05%
	Clobetasol propionate	Cream, Ointment	0.05%
	Diflorasone diacetate	Ointment	0.05%
	Halobetasol propionate	Cream, Ointment	0.05%
II.	<i>High potency</i>		
	Amcinonide	Cream, Lotion, Ointment	0.1%
	Augmented betamethasone dipropionate	Cream, Lotion	0.05%
	Betamethasone	Cream, Ointment	0.05%
	Betamethasone valerate	Ointment	0.1%
	Desoximetasone	Cream, Ointment	0.25%
		Gel	0.05%
	Diflorasone diacetate	Cream, Ointment (emollient base)	0.05%
	Fluocinonide	Cream, Ointment, Gel	0.05%
	Halcinonide	Cream, Ointment	0.1%
	Triamcinolone acetonide	Cream, Ointment	0.5%
III.	<i>Medium potency</i>		
	Betamethasone	Lotion	0.05%
	Betamethasone valerate	Cream	0.1%



**EUCRISA
(crisaborole)**

III.	Clocortolone pivalate	Cream	0.1%
	Desoximetasone	Cream	0.05%
	Fluocinolone acetonide	Cream, Ointment	0.025%
	Flurandrenolide	Cream, Ointment, Lotion	0.05%
		Tape	4 mcg/cm ²
	Fluticasone propionate	Cream	0.05%
		Ointment	0.005%
	Hydrocortisone butyrate	Ointment, Solution	0.1%
	Hydrocortisone valerate	Cream, Ointment	0.2%
	Mometasone furoate	Cream, Ointment, Lotion	0.1%
	Prednicarbate ²	Cream, Ointment	0.1%
	Triamcinolone acetonide	Cream, Ointment, Lotion	0.025%
		Cream, Ointment, Lotion	0.1%
IV.	<i>Low potency</i>		
	Alclometasone dipropionate	Cream, Ointment	0.05%
	Desonide	Cream	0.05%
	Fluocinolone acetonide	Cream, Solution	0.01%
	Hydrocortisone	Lotion	0.25%
		Cream, Ointment, Lotion, Aerosol	0.5%
		Cream, Ointment, Lotion, Solution	1%
		Cream, Ointment, Lotion	2.5%
	Hydrocortisone acetate	Cream, Ointment	0.5%
		Cream, Ointment	1%